Scangos George A's Form 4 filing
Vir Biotechnology, Inc. (VIR) · filed Feb 21, 2023
- Accession no.
- 0001209191-23-011387
- Filed
- Feb 21, 2023
- Trade date
- Dec 21, 2022-Feb 21, 2023
- Filing delay
- 62 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 9 non-derivative transactions. Open-market sales total $755.6K. It was filed 62 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scangos George ACIK 0001202102 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2022 | Common Stock | JOtherDisposed | −49,984 | $0.00 | $0 | 827,151 | Indirect | |
| Dec 21, 2022 | Common Stock | JOtherAcquired | +49,984 | $0.00 | $0 | 111,644 | Indirect | |
| Dec 21, 2022 | Common Stock | JOtherDisposed | −49,984 | $0.00 | $0 | 827,151 | Indirect | |
| Dec 21, 2022 | Common Stock | JOtherAcquired | +49,984 | $0.00 | $0 | 111,644 | Indirect | |
| Jan 18, 2023 | Common Stock | JOtherDisposed | −64,930 | $0.00 | $0 | 3,533,629 | Indirect | |
| Jan 18, 2023 | Common Stock | JOtherAcquired | +64,930 | $0.00 | $0 | 179,930 | Indirect | |
| Feb 17, 2023 | Common Stock | SSaleDisposed | −9,894 | $25.29 | −$250,219.26 | 214,095 | Direct | |
| Feb 21, 2023 | Common Stock | SSaleDisposed | −11,382 | $28.02F10 | −$318,923.64 | 202,713 | Direct | |
| Feb 21, 2023 | Common Stock | SSaleDisposed | −6,474 | $28.80F11 | −$186,451.2 | 196,239 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F10
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F11
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.51 to $29.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.